Evaluation of Therapeutic Response Between Idiopathic Inflammatory Myopathies and Autoimmune Necrotizing Myopathies at a Tertiary Neuromuscular Center (P1.113)

Conclusions:Gender and age demographics for IIM and ANM patients in our retrospective review were similar to those found in published literature. The results of therapeutic response for both groups will be presented at the conference.Disclosure: Dr. Murphy has nothing to disclose. Dr. Dimachkie has received personal compensation for activities with Pfizer, Depomed, Merck, CSL-Behring, Nufactor, Biomarin, Baxter and Catalyst as a consultant and/or speaker. Dr. Jawdat has nothing to disclose. Dr. Statland has received personal compensation for activities with Sarepta, ATYR Bristol Meyers Squib, Acceleron, Clinical Mind, and Novartis as a advisor and/or consultant. Dr. Glenn has nothing to disclose. Dr Barohn received personal compensation for activities with Grifols & Genzyme as a member of the Speakers Bureau and NuFactor as a consultant. Dr. Herbelin has nothing to disclose. Dr. Pasnoor has nothing to disclose.
Source: Neurology - Category: Neurology Authors: Tags: Myopathies & amp;amp; Myasthenia Gravis I Source Type: research